Free Trial

FibroBiologics Q2 2024 Earnings Report

FibroBiologics logo
$1.12 -0.12 (-9.27%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FibroBiologics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.09
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

FibroBiologics Earnings Headlines

FibroBiologics' (FBLG) Buy Rating Reiterated at D. Boral Capital
FibroBiologics' (FBLG) "Buy" Rating Reaffirmed at HC Wainwright
Grab This Altcoin Before Trump's Crypto Announcement
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
FibroBiologics files $50M mixed securities shelf
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG) operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile

More Earnings Resources from MarketBeat